716-11-0

A positively charged guanidium-containing quinazoline that modulates ASIC function by blocking acid-induced maximal peak current as well as by altering ASICs pH dependence for activation and inactivation, enabling a partial, but sustained ASIC3 activation around neutral pH, which is inhibitable by Amiloride. Intraplantar paw injection (10 µL 100 µM) is reported to elicit a pain response in asic3^+/+, but not asic3^-/-, mice in vivo. GMQ targeting area appears to overlap with Amiloride binding site in the pore region, but is distinct from ASIC calcium binding site.

Primary Target
ASIC3''Reversible: yes